- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non small cell lung cancer (NSCLC)
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 1MB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 556KB)
Cemiplimab – November 2023
Cemiplimab: Solution for I.V. infusion 350 mg in 7 mL; Libtayo®
Last updated
1 March 2024